Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$14.05 USD

14.05
4,310,210

-0.26 (-1.82%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.04 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks News

Zacks Equity Research

Medtronic (MDT) Launches Telescope Guide Extension Catheter

The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.

Zacks Equity Research

ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

Zacks Equity Research

Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

Zacks Equity Research

Varian Medical Installs ProBeam at Research Hub in Singapore

Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.

Zacks Equity Research

Integra LifeSciences Rides on Product Launch, Faces Rivalry

Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.

Zacks Equity Research

STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.

Zacks Equity Research

Medtronic to Acquire Titan Spine for Spine Portfolio Boost

According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.

Zacks Equity Research

ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals

ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.

Zacks Equity Research

Abbott Rides on Strong CGM, Poor Rhythm Management Ails

Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.

Zacks Equity Research

Medtronic's (MDT) EV ICD Pilot Study Results Encourage

The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.

Zacks Equity Research

Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y

Nevro's (NVRO) domestic and international revenues fall year over year in Q1.

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

Illumina (ILMN) has been gaining investor confidence on robust performance.

Zacks Equity Research

National Vision's (EYE) Q1 Earnings Beat, Margins Decline

National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.

Zacks Equity Research

Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line

Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.

Zacks Equity Research

LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1

LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.

Zacks Equity Research

BioScrip's Option Care Merger on Track, Q1 Loss Narrows

BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

Zacks Equity Research

Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag

Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

Zacks Equity Research

Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates

Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.

Zacks Equity Research

OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates

Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.

Zacks Equity Research

Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y

Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.

Zacks Equity Research

Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall

Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.

Zacks Equity Research

McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates

McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.

Zacks Equity Research

Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat

Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.